Clinical Trials Logo

Severe Tricuspid Regurgitation clinical trials

View clinical trials related to Severe Tricuspid Regurgitation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04141137 Completed - Clinical trials for Severe Tricuspid Regurgitation

TRICUS STUDY Euro - Safety and Efficacy of the TricValve® Device

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

The TricValve® Transcatheter Bicaval Valves System is indicated for relief of tricuspid insufficiency in patients with symptomatic heart disease who are judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy.

NCT ID: NCT03723239 Completed - Clinical trials for Severe Tricuspid Regurgitation

TRICUS STUDY - Safety and Efficacy of the TricValve® Device

Start date: September 12, 2018
Phase: N/A
Study type: Interventional

The TricValve® Transcatheter Bicaval Valves System is indicated for relief of tricuspid insufficiency in patients with symptomatic heart disease who are judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy.

NCT ID: NCT03416166 Recruiting - Clinical trials for Severe Tricuspid Regurgitation

International Multisite Transcatheter Tricuspid Valve Therapies Registry

TriValve
Start date: November 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

For a long time, tricuspid valve disease has been considered as less important than left-sided valvular heart disease. If treated in an advanced stage and simultaneously with other cardiac diseases, it is associated with significant morbidity and mortality. Hence, physicians tend to refer patients more aggressively to surgery (1). Transcatheter procedures are an attractive alternative in high-risk patients. The field of transcatheter tricuspid devices has rapidly advanced over the last few years (2). Limited knowledge is available regarding the epidemiologic and anatomical settings in which these therapies are preferentially applied. The main purpose of this registry is the collection of baseline clinical and anatomical data of the patients treated with transcatheter tricuspid valve therapies, and their outcomes, whenever feasible. Apart from more knowledge regarding the current status in this field, the results could also help the establishment of guidelines with respect to the choice of the transcatheter device selected and to understand which therapy can provide the better outcome in the different anatomies. Moreover, this study will provide important information about the epidemiology of severe tricuspid regurgitation, which is at the moment an undertreated disease.

NCT ID: NCT02387697 Terminated - Clinical trials for Severe Tricuspid Regurgitation

Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)

Start date: January 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of implanting an Edwards Sapien XT Valve into the vena cava inferior (VCI; between right atrium and the hepatic vein) on clinical variables, exercise tolerance and well being in patients with severe tricuspid regurgitation and signs of right heart failure.